Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Platform Study for MRD-positive AML
NCT07131059Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2024
- Primary completion
- May 2028
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of ivosidenib, gilteritinib, venetoclax, avapritinib, daunorubicin and 7 more in acute myeloid leukemia (AML) (9 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Relapse-Free Survival Rate at 6 months. Started May 2024; status: recruiting.
02
Drugs
ivosidenibgilteritinibvenetoclaxavapritinibdaunorubicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07131059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07131059.